You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma

  • Technology appraisal guidance
  • Reference number: TA695
  • Published:  28 April 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Declaration of interests
  3. Final draft guidance
  4. Draft guidance
  5. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 161 KB)

    Published:
    28 April 2021

Declaration of interests

  • Register of interests (PDF 159 KB)

    Published:
    28 April 2021

Final draft guidance

  • Final draft guidance

  • Committee papers (PDF 852 KB)

    Published:
    19 March 2021
  • Public committee slides (PDF 671 KB)

    Published:
    19 March 2021
  • Final appraisal document (PDF 244 KB)

    Published:
    19 March 2021

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF version) (PDF 248 KB)

    Published:
    22 September 2020
  • Appraisal consultation document (online commenting)

  • Committee papers (PDF 4.02 MB)

    Published:
    22 September 2020
  • Public committee slides (PDF 807 KB)

    Published:
    22 September 2020

Invitation to participate

  • Final stakeholder list (PDF 184 KB)

    Published:
    30 August 2019
  • Draft scope and provisional stakeholder list comments table (post-referral) (PDF 328 KB)

    Published:
    30 August 2019
  • Equality impact assessment (Scoping) (PDF 127 KB)

    Published:
    30 August 2019
  • Final scope (PDF 181 KB)

    Published:
    30 August 2019
Back to top